"Monoclonal antibody research skyrocketed in the 1980s. By the next decade, they hit the market and today, some of the drugs with the highest revenue are the “mabs” – Humira, Remicade, Rituxan, Avastin and Herceptin."
"The market will work the same way with nanomedicine, projects Jeff Hrkach, former Chief Technological Officer at BIND Therapeutics. 'Nanomedicines can become the third pillar of drug development,' following pharmaceuticals and biologics – bringing physics more into play in the life sciences, he said. "
From MedCity News: http://ow.ly/OCUhi
#BIO2015: Nanomedicine… the next big thing? – MedCity News
Nanomedicine is emerging in the life sciences as a potent way to enhance drug performance – but the applications don’t stop there, a panel of proponents say.
Post imported by Google+Blog for WordPress.